Description
Mod GRF 1-29 & Ipamorelin Peptide Blend
Ipamorelin is a synthetic pentapeptide studied for its potential role as a growth hormone secretagogue (GHS). It is believed to act similarly to ghrelin, the so-called “hunger hormone,” by binding to ghrelin receptors (GHS-R1a) in the anterior pituitary. This selective activation may stimulate the release of growth hormone without significantly affecting other pituitary hormones such as prolactin, FSH, LH, TSH, or ACTH, making it relatively targeted compared to other secretagogues.
Modified GRF 1-29 (also called Mod GRF 1-29) is a laboratory-made analog of growth hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of the natural hormone, with four substitutions introduced to improve stability and resistance to enzymatic breakdown. These changes are intended to extend its half-life and enhance its pharmacokinetic properties. It is also commonly referred to as CJC-1295 without DAC.
When combined, Mod GRF 1-29 and Ipamorelin are thought to act synergistically by stimulating growth hormone release through complementary pathways.
Chemical characteristics
- Modified GRF 1-29: C152H252N44O42; ~3367.95 g/mol
- Ipamorelin: C38H49N9O5; ~711.86 g/mol
Alternative names include Mod GRF 1-29 (CJC-1295 without DAC) and Ipamorelin acetate (Aib-His-D-2-Nal-D-Phe-Lys-NH2).
Research overview
Early animal and laboratory studies suggest these peptides influence growth hormone secretion through pituitary signaling pathways.
Growth hormone release and mechanism
Mod GRF 1-29 is thought to activate GHRH receptors on pituitary somatotroph cells. This may trigger intracellular signaling involving the adenylyl cyclase pathway, increasing cAMP levels, activating protein kinase A, and leading to calcium channel phosphorylation. The resulting calcium influx is believed to promote growth hormone release.
Ipamorelin, meanwhile, is thought to bind GHS-R1a receptors and activate G-protein–linked signaling pathways (notably Gαq/11 and PLC), generating secondary messengers (IP3 and DAG). This process may increase intracellular calcium release and further stimulate growth hormone secretion.
Together, these pathways are proposed to produce a combined or synergistic increase in growth hormone output.
Physiological and experimental findings
Appetite and metabolism
Ipamorelin’s interaction with ghrelin receptors suggests a possible increase in appetite and food intake. Some animal studies report increased body weight and fat mass, potentially linked to greater food consumption and hormonal changes such as leptin signaling.
Bone and muscle effects
Experimental research in animal models indicates possible increases in bone mineral content and improvements in bone density markers. Some findings also suggest preservation or enhancement of muscle mass under catabolic conditions.
Gastrointestinal effects
Ipamorelin has been observed in some studies to accelerate gastric emptying and influence smooth muscle contractility in the digestive tract, possibly affecting gastrointestinal motility.
Endocrine effects
Studies suggest that growth hormone levels rise after administration of these peptides, with potential downstream increases in IGF-1. Some reports indicate stronger effects when GHRH analogs and GHRP compounds are used together, possibly producing higher pulsatile growth hormone release than either compound alone.
Summary
Overall, Mod GRF 1-29 and Ipamorelin are studied primarily for their potential to stimulate growth hormone secretion through different but complementary receptor pathways. Mod GRF acts through GHRH receptor signaling, while Ipamorelin acts through ghrelin receptor activation. When combined, they are theorized to produce amplified growth hormone release, with associated research exploring effects on metabolism, appetite, bone density, and body composition in experimental models.
These compounds are generally described in research contexts as investigational and are not established medical therapies.
Reviews
There are no reviews yet.